+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Merkel Cell Carcinoma Pipeline Analysis and Outlook, 2019

  • ID: 4772514
  • Report
  • May 2019
  • Region: Global
  • 121 pages
  • VPA Research


  • Amgen Inc
  • BeiGene Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck Group
  • NeoImmuneTech
  • Ono Pharmaceutical Co Ltd
Merkel Cell Carcinoma pipeline

Merkel Cell Carcinoma pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Merkel Cell Carcinoma R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Merkel Cell Carcinoma report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Merkel Cell Carcinoma as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Merkel Cell Carcinoma with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Merkel Cell Carcinoma pipeline Profiled in detail

Key players actively participating in Merkel Cell Carcinoma pipeline are profiled along with their R&D progress in Merkel Cell Carcinoma treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Merkel Cell Carcinoma pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Merkel Cell Carcinoma treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Merkel Cell Carcinoma pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Merkel Cell Carcinoma pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Merkel Cell Carcinoma pipeline study
  • All recent news and developments related to Merkel Cell Carcinoma drugs are provided
Note: Product cover images may vary from those shown


  • Amgen Inc
  • BeiGene Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck Group
  • NeoImmuneTech
  • Ono Pharmaceutical Co Ltd
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Merkel Cell Carcinoma Disease Overview

3. Merkel Cell Carcinoma Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Merkel Cell Carcinoma Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Merkel Cell Carcinoma Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Merkel Cell Carcinoma companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Merkel Cell Carcinoma Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
  • Altor BioScience Corporation
  • Amgen Inc
  • Apcure SAS
  • Bavarian Nordic A/S
  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Checkpoint Therapeutics Inc
  • CStone Pharmaceuticals Australia Pty Ltd
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Immune Design Corp Incyte Corp
  • Kartos Therapeutics Inc
  • Merck Group
  • Millennium Pharmaceuticals Inc
  • NantKwest Inc
  • Nektar Therapeutics
  • NeoImmuneTech
  • Novartis AG
  • OncoSec Medical Inc
  • Ono Pharmaceutical Co Ltd
  • QBiotics Ltd
  • Replimune Ltd
  • Tarveda Therapeutics Inc
  • Trillium Therapeutics Inc
Note: Product cover images may vary from those shown